Ligand validation:3ZNM

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 3ZNM designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3ZNM_NAG_C_1322	62%	59%	0.102	0.894	0.49	1.06	-	1	0	0	100%	0.9333
3ZNM_NAG_A_1322	48%	64%	0.158	0.9	0.46	0.92	-	-	0	0	100%	0.9333
3ZNM_NAG_E_1322	43%	55%	0.154	0.876	0.44	1.27	-	2	1	0	100%	0.9333
3ZNM_NAG_F_1164	41%	53%	0.162	0.878	0.51	1.29	-	1	0	1	100%	0.9333
3ZNM_NAG_A_1323	38%	44%	0.152	0.853	0.64	1.49	-	3	0	0	100%	0.9333
3ZNM_NAG_C_1323	32%	44%	0.164	0.836	0.63	1.5	-	2	0	0	100%	0.9333
3ZNM_NAG_B_1164	25%	66%	0.213	0.851	0.46	0.83	-	-	0	1	100%	0.9333
3ZNM_NAG_D_1164	25%	47%	0.209	0.843	0.44	1.56	-	2	0	1	100%	0.9333
3ZNM_NAG_E_1323	22%	44%	0.186	0.799	0.58	1.55	-	3	0	0	100%	0.9333
4BH0_NAG_A_1320	84%	50%	0.074	0.935	0.49	1.4	-	2	0	0	100%	0.9333
4CR0_NAG_A_1165	83%	51%	0.112	0.97	0.49	1.37	-	1	0	0	100%	0.9333
4KDQ_NAG_E_502	81%	59%	0.104	0.957	0.53	1.02	-	2	2	0	100%	0.9333
4BGZ_NAG_C_503	71%	53%	0.082	0.901	0.45	1.34	-	2	0	0	100%	0.9333
4K64_NAG_A_601	70%	61%	0.125	0.942	0.51	0.97	-	1	0	0	100%	0.9333
3H0C_NAG_A_794	100%	56%	0.021	0.995	0.61	1.08	-	1	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3GXM_NAG_A_498	100%	45%	0.026	0.992	0.75	1.34	-	2	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.